OncLive TV

Dr. Heinemann on Using Depth of Response in Pretreated Patients With CRC

August 22nd 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses using depth of response as an appropriate endpoint in studies examining patients with metastatic colorectal cancer (mCRC).

Dr. Jeffrey S. Weber on Why the Results of CheckMate-064 Were Surprising

August 21st 2016

Early Promise of Radiation Plus PCV in Patients With Low-Grade Glioma

August 19th 2016

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Dr. Federman on Challenges With Treating AYA Patients With Sarcoma

August 19th 2016

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles, discusses the challenges associated with treating adolescent and young adult (AYA) patients with sarcoma.

Dr. Pecora on Oncology Care Model Innovations

August 19th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Oncology Care Model (OCM) and other aspects of healthcare reform.

Dr. Henricus de Koning on Screening in NSCLC

August 19th 2016

Dr. Baas on Next Steps in the Treatment of Mesothelioma

August 19th 2016

Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

Dr. Michael J. Overman on Immunotherapy in Colorectal Cancer

August 19th 2016

Dr. Kay on Genetic Investigations in Chronic Lymphocytic Leukemia

August 18th 2016

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the genetic investigations being conducted in chronic lymphocytic leukemia (CLL), and more specifically, monoclonal b-cell lymphocytosis, which resembles CLL but does not meet the same criteria.

Dr. Rudin on Rova-T in Patients With Small Cell Lung Cancer

August 18th 2016

Charles M. Rudin, MD, medical oncologist, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the safety and efficacy of single-agent rovalpituzumab tesirine (Rova-T) in patients with recurrent or refractory small cell lung cancer (SCLC).

Dr. Hudis on Combating Obesity in Breast Cancer

August 18th 2016

Clifford A. Hudis, MD, CEO, ASCO, discusses how oncologists should be helping patients with breast cancer overcome obesity.

Dr. Edward S. Kim on his "Wish List" for the Future of Immunotherapy in NSCLC

August 18th 2016

Patient Resistance to Swallowing Exercises After Multimodality Therapy

August 17th 2016

Giselle Carnaby, PhD, professor, ASHA fellow, Communication Sciences and Disorders, University of Central Florida, discusses rehabilitation of swallowing after multimodality therapy in patients with head and neck cancer, and why they may be resistant to it.

Dr. Lonial on Daratumumab Plus Pomalidomide in Multiple Myeloma

August 17th 2016

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the potential of the combination regimen of pomalidomide (Pomalyst) and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Dr. Joyce O'Shaughnessy on Promising Agents in Triple-Negative Breast Cancer

August 17th 2016

Joyce O'Shaughnessy, MD, co-chair, breast cancer research, chair breast cancer at Baylor-Sammons Cancer Center, discusses what’s on the horizon in triple-negative breast cancer (TNBC). Checkpoint inhibitors, such as an anti-PD-1 agents, show a lot of promise in TNBC, said O’Shaughnessy. There are several studies investigating the use of checkpoint inhibitors with platinum agents and the preliminary data looks very good, she said.

Dr. Mohammed Haseebuddin on PD-1 Expression in RCC

August 17th 2016

Dr. Alexander I. Sankin on HHLA2 in Bladder Cancer

August 17th 2016

Dr. Hurvitz on Steps to Take With HER2-Positive Breast Cancer Research

August 17th 2016

Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses steps needed to take in the field of HER2-positive breast cancer from a research perspective.

Dr. Paty on Patients With Rectal Cancer Ineligible for "Watch and Wait"

August 17th 2016

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses patients with rectal cancer who are ineligible for a "watch and wait" approach with their surgeons.

Dr. Joshua M. Bauml on Pembrolizumab Versus Chemo in Head and Neck Cancers

August 16th 2016

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.